S&P Keeps Pfizer, Merck at Hold

Analyst Herman Saftlas also keeps his target prices on the Big Pharma stalwarts amid news on Celebrex and Vioxx. Plus: Opinions on Merck, AIG, and more

Pfizer (PFE ): Reiterates 3 STARS (hold)

To continue reading this article you must be a Bloomberg Professional Service Subscriber.